Chemo-enzymatic synthesis of pharmaceutical intermediates

Expert Opinion on Drug Discovery

Volumn 3, Issue 2, 2008, Pages 187-245

  Patel, Ramesh N ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Biocatalysis; Chiral intermediates; Enzymatic processes; Pharmaceuticals development

Indexed keywords

ALPHA2B INTERFERON; ATAZANAVIR; BUSPIRONE; CARBOVIR; CATHEPSIN S; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; EPOTHILONE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; INOGATRAN; LOBUCAVIR; NEUROLEPTIC AGENT; OMAPATRILAT; PACLITAXEL; PLEUROMUTILIN; POTASSIUM CHANNEL STIMULATING AGENT; PROPRANOLOL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RETINOIC ACID DERIVATIVE; RETINOID; RIBAVIRIN; SITAGLIPTIN; SPERGUALIN; TAXANE DERIVATIVE; THROMBIN INHIBITOR; TIGEMONAM; UNINDEXED DRUG; XEMILOFIBAN; ZANAMIVIR;

ACNE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACYLATION; AMINATION; AMINOACYLATION; ANXIETY DISORDER; AUTOIMMUNE DISEASE; BAEYER VILLIGER REACTION; BIOTRANSFORMATION; BREAST CANCER; CHIRALITY; DEPRESSION; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; ENANTIOSELECTIVITY; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME KINETICS; ENZYME SYNTHESIS; FERMENTATION; HEPATITIS B; HEPATITIS C; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROLYSIS; HYDROXYLATION; HYPERTENSION; INFLUENZA; NONHUMAN; OVARY CANCER; OXIDATION; OXYGENATION; PRIORITY JOURNAL; PSORIASIS; REDUCTION; REVIEW; SKIN DISEASE; THROMBOSIS; TRANSAMINATION; TUMOR; UNSPECIFIED SIDE EFFECT;

EID: 39649108652     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.2.187     Document Type: Review

References (290)

1. Food & Drug Administration: FDA's statement for the development of new stereoisomeric drugs. Chirality 1992;4:338-40
2. Oliver M, Voigt CA, Arnold FH. Enzyme engineering by directed evolution. Enzyme Catalysis in Organic Synthesis (2nd Edition) 2002;1:95-138
3. Kazlauskas RJ. Enhancing catalytic promiscuity for biocatalysis. Curr Opin Chem Biol 2005;9(2):195-201
4. Schmidt M, Baumann M, Henke E, et al. Directed evolution of lipases and esterases. Methods Enzymol (Protein Eng) 2004;388:199-207
5. Reetz MT, Torre C, Eipper A, et al. Enhancing the enantioselectivity of an epoxide hydrolase by directed evolution. Org Lett 2004;6(2):177-80
6. Otey CR, Bandara G, Lalonde J, et al. Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450. Biotech Bioeng 2006;93(3):494-9
7. Huisman GW, Lalonde JJ. Enzyme evolution for chemical process applications. Biocatalysis in the Pharmaceutical and Biotechnology Industries. Patel RN, editor, CRC Press, FL. 2007. p. 717-42
8. Huisman GW, Gray D. Towards novel processes for the fine-chemical and pharmaceutical industries. Curr Opin Biotechnol 2002; 13(4):352-8
9. Alphand V, Carrea G, Wohlgemuth R, et al. Towards large-scale synthetic applications of Baeyer-Villiger monooxygenases. Trends Biotechnol 2003;21(7):318-23
10. DiCosimo R. Nitrilases and nitrile hydratases. Biocatalysis in the Pharmaceutical and Biotechnology Industries. Patel RN, editor, CRC Press, FL. 2007. p. 1-26
11. Patel RN. Biocatalysis: synthesis of chiral intermediates for pharmaceuticals. Curr Org Chem 2006;10(11):1289-321
12. Simeo Y, Kroutil W, Faber K. Biocatalytic deracemization: dynamic resolution, stereoinversion, enantioconvergent processes, and cyclic deracemization. Biocatalysis in the Pharmaceutical and Biotechnology Industries. Patel RN, editor, CRC Press, FL. 2007. p. 27-51
13. Simons C, Hanefeld U, Arends IWCE, et al. Towards catalytic cascade reactions: asymmetric synthesis using combined chemo-enzymatic catalysts. Top Catalysis 2006;40(1-4):35-44
14. Turner NJ. Enzyme catalyzed deracemization and dynamic kinetic resolution reactions. Curr Opin Chem Biol 2004;8(2):114-9
15. Robertson DE, Bornscheuer UT. Biocatalysis and biotransformation new technologies, enzymes and challenges. Curr Opin Chem Biol 2005; 9(2):164-5
16. Ishige T, Honda K, Shimizu S. Whole organism biocatalysis. Curr Opin Chem Biol 2005; 9(2):174-80
17. Stewart JD. Green chemical manufacturing with biocatalysis. Environ Catalysis 2005;649-65
18. Fessner W-D, Jennewein S. Biotechnological applications of aldolases. Biocatalysis in the Pharmaceutical and Biotechnology Industries. Patel RN, editor, CRC Press, FL. 2007. p. 363-400
19. Boyd DR, Bugg TDH. Arene cis-dihydrodiol formation: from biology to application. Org Biomol Chem 2006;4(2):181-92
20. Pollard DJ, Woodley JM. Biocatalysis for pharmaceutical intermediates: The future is now. Trends Biotechnol 2007;25(2):66-73
21. Pohl M, Liese A. Industrial processes using lyases for C-C, C-N, and C-C bond formation. In: Biocatalysis in the Pharmaceutical and Biotechnology Industries. Patel RN, editor, CRC Press, FL. 2006. p. 661-76
22. Effenberger F. Hydroxynitrile lyases in stereoselective synthesis in Stereoselective Biocatalysis, Patel RN, editor, Marcel Dekker, NY. 2000. p. 321-42
23. Biocatalysis. Bommarius AS, Riebel BR, editors, Wiley-VCH. 2004
24. Biotransformations in Organic Chemistry. Faber K, editor, Springer. 2005
25. Buchholz K, Kasche V, Bornscheuer UT. Biocatalysts and Enzyme Technology. Wiley-VCH. 2005
26. Industrial Biotransformations. Liese A, Seelbach K, Wandrey C, editors, Wiley-VCH. 2006
27. Biocatalysis in the Pharmaceutical and Biotechnology Industries. Patel RN, editor, CRC Press, FL. 2007
28. Wandrey C, Wichmann R, Leuchtenberger W, et al. Continuous enzymic transformation of water-soluble α-keto carboxylic acids into the corresponding amino acids. Eur Pat Appl 1981. 14pp
29. Brunhuber NM, Blanchard JS. The biochemistry and enzymology of amino acid dehydrogenases. Crit Rev Biochem Mol Biol 1994;29(6):415-67
30. Bommarius AS. Reduction of C=N bonds. Enzyme Catalysis in Organic Synthesis (2nd Edition) 2002. p. 1047-63
31. Hanson RL, Singh J, Kissick TP, et al. Synthesis of L-β-hydroxyvaline from α-keto-βhydroxyisovalerate using leucine dehydrogenase from Bacillus species. Bioorg Chem 1990; 18(2):116-30
32. Robl J, Sun C, Stevenson J. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1997;40:1570-7
33. Hanson RL, Schwinden MD, Banerjee A, et al. Enzymatic synthesis of L-6-hydroxynorleucine. Bioorg Med Chem 1999;7(10):2247-52
34. Patel R. Enzymatic synthesis of chiral intermediates for omapatrilat, an antihypertensive drug. Biomol Eng 2001;17:167-82
35. Hanson RL, Howell J, LaPorte T, et al. Synthesis of allylsine ethylene acetal using phenylalanine dehydrogenase from Thermoactinomyces intermedius. Enz Microb Technol 2000;26:348-58
36. Schütte H, Flossdorf J, Sahm H, et al. Purification and properties of formaldehyde dehydrogenase and formate dehydrogenase from Candida boidinii. Eur J Biochem 1976;62:151-60
37. Hou CT, Patel RN, Laskin AI, et al. NAD-linked formate dehydrogenase from methanol-grown Pichia pastoris NRRL-Y-7556. Arch Biochem Biophys 1982;216(1):296-305
38. Gallwitz B. Glucagon-like peptide-1-based therapies for the treatment of Type 2 diabetes mellitus. Treat Endocrinol 2005;4:361-70
39. Sinclair EM, Drucker DJ. Glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of Type 2 diabetes. Curr Opin Endocrinol Diabet 2005;12:146-51
40. Augeri DJ, Robl JA, Betebenner DA, et al. A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes. J Med Chem 2005;48:5025-37
41. Vu TC, Brzozowski DB, Fox R, et al. Preparation of cyclopropyl-fused pyrrolidine based inhibitors of dipeptidyl peptidase IV. WO2004052850 (2004)
42. Hanson RL, Goldberg SL, Brzozowski DB, et al. Preparation of an amino acid intermediate for the dipeptidyl peptidase IV inhibitor, saxagliptin, using a modified phenylalanine dehydrogenase. Adv Synthesis Catalysis 2007; 349(8+9):1369-78
43. Asano Y. Enzymatic synthesis of (S)-phenylalanine and related (S)-amino acids by phenylalanine dehydrogenase. Methods Biotechnol (Microbial Enzymes Biotransformations) 2005;17:141-50
44. Cainelli C, Engel PC, Galletti P, et al. Engineered phenylalanine dehydrogenase in organic solvents: homogeneous and biphasic enzymatic reactions. Org Biomol Chem 2005;3(24):4316-20
45. Bold G, Faessler A, Capraro H-G, et al. New aza-dipeptide analogs as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. J Med Chem 1998; 41(18):3387-401
46. Robinson BS, Riccardi KA, Gong YF, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000;44(8):2093-9
47. Stoyan T, Recktenwald A, Kula MR. Cloning, sequencing and overexpression of the leucine dehydrogenase gene from Bacillus cereus. J Biotechnol 1997;54(1):77-80
48. Menzel A, Werner H, Altenbuchner J, et al. From enzymes to "designer bugs" in reductive amination: a new process for the synthesis of L-tert-leucine using a whole cell-catalyst. Eng Life Sci 2004;4(6):573-6
49. Groeger H, May O, Werner H, et al. A "second-generation process" for the synthesis of L-neopentylglycine: asymmetric reductive amination using a recombinant whole cell catalyst. Org Process Res Dev 2006;10(3):666-9
50. Emmanuel MJ, Frye LL, Hickey ER, et al. Novel spiroheterocyclic compounds [morpholine-4-carboxylic acid amides of heterocyclic cyclohexylalanine and neopentylglycine derivatives and their analogs], useful as reversible inhibitors of cysteine proteases such as cathepsin S. WO2001019816 (2001)
51. Mihara H, Muramatsu H, Kakutani R, et al. N-methyl-L-amino acid dehydrogenase from Pseudomonas putida. A novel member of an unusual NAD(P)-dependent oxidoreductase superfamily. FEBS J 2005; 272(50):1117-23
52. Kato Y, Yamada H, Asano Y. Stereoselective synthesis of opine-type secondary amine carboxylic acids by a new enzyme opine dehydrogenase. Use of recombinant enzymes. J Mol Catalysis B Enzymatic 1996;1(3-6):151-60
53. Merviel P, Najas S, Campy H, et al. Use of GNRH antagonists in reproductive medicine. Minerva Ginecol 2005;57(1):29-43
54. Hauptmann J. Pharmacokinetics of an emerging new class of anticoagulant antithrombotic drugs. A review of small-molecule thrombin inhibitors. Eur J Clin Pharmacol 2002; 57(11):751-58
55. Straathof AJJ, Panke SA. The production of fine chemicals by biotransformations. Curr Opin Bin technol 2002; 13(6):548-56
56. Bommarius AS, Schwarm M, Drauz K. Biocatalysis to amino acid-based chiral pharmaceuticals-examples and perspectives. J Mol Catalysis B Enzymatic 1998;5(1-4):1-11
57. Vedha PK, Gunawardana M, Rozzell DJ, et al. Creation of a broad-range and highly Stereoselective D-amino acid dehydrogenase for the one-step synthesis of D-amino acids. J Am Chem Soc 2006; 128(33):10923-9
58. Gustafsson D, Elg M, Lenfors S, et al. Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. Blood Coagul Fibrinolysis 1996; 7(1):69-79
59. Patel RN, Chu L, Mueller RH. Diastereoselective microbial reduction of (S)-[3-chloro-2-oxo-1 (phenylmethyl) propyl]carbamic acid, 1,1-dimethylethyl ester. Tetrahedron:Asymmetry 2003; 14(20):3105-9
60. Jajoo HK, Mayol RF, LaBudde JA, et al. Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos 1989;17(6):634-40
61. Mayol RF. Buspirone metabolite for the alleviation of anxiety. US6150365 (2000)
62. Yevich JP, New JS, Lobeck WG, et al. Synthesis and biological characterization of α-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogs as potential atypical antipsychotic agents. J Med Chem 1992;35(24):4516-25
63. Yevich JP, Mayol RF, Li J, et al. (S)-6-Hydroxy-buspirone for treatment of anxiety, depression and related disorders. US2003022899 (2003)
64. Patel RN, Chu L, Nanduri V, et al. Enantioselective microbial reduction of 6-oxo-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5] decane-7,9-dione. Tetrahedron:Asymmetry 2005;16(16):2778-83
65. Goldberg SL, Nanduri VB, Chu L, et al. Enantioselective microbial reduction of 6-oxo-8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5] decane-7,9-dione: cloning and expression of reductases. Enzyme Microb Technol 2006;39(7):1441-50
66. Wittman M, Carboni J, Attar R, et al. Discovery of a 1H-benzoimidazol-2-yl-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J Med Chem 2005;48(18):5639-43
67. Wittman MD, Balasubramanian B, Stoffan K, et al. Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase. Bioorg Med Chem Lett 2007; 17(4);974-7
68. Hanson RL, Goldberg S, Goswami A, et al. Purification and cloning of a ketoreductase used for the preparation of chiral alcohols. Adv Synthesis Catalysis 2005; 347(7+8):1073-80
69. Patel RN, Banerjee A, McNamee CC, et al. Enantioselective microbial reduction of 3,5-dioxo-6-(benzyloxy) hexanoic acid, ethyl ester. Enzyme Microb Technol 1993;15(12):1014-21
70. Roth BD. The discovery and development of atorvastatin, a potent novel hypolipidemic agent. Prog Med Chem 2002;40:1-22
71. Guo Z, Chen Y, Goswami A, et al. Synthesis of ethyl and t-butyl (3R,5S)-dihydroxy-6-benzyloxy hexanoates via diastereo- and enantioselective microbial reduction. Tetrahedron:Asymmetry 2006;17(1):1589-602
72. Vacca JP. New advances in the discovery of thrombin and factor Xa inhibitors. Curr Opin Chem Biol 2000;4(4):394-400
73. Gladwell TD. Bivalirudin. A direct thrombin inhibitor. Clin Ther 2002;24(1):38-58
74. Fevig JM, Wexler RR. Anticoagulants: thrombin and factor Xa inhibitors. Annu Rep Med Chem 1999;34:81-100
75. Williams PD, Coburn C, Burgey C, et al. Preparation of triazolopyrimidines as thrombin inhibitors. WO2002064211 (2002)
76. Nelson TD, LeBlond CR, Frantz DE, et al. Stereoselective synthesis of a potent thrombin inhibitor by a novel P2-P3 lactone ring opening. J Org Chem 2004;69(11):3620-7
77. Kagechika H, Kawachi E, Hashimoto Y, et al. Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J Med Chem 1989;32(12):2583-8
78. Kagechika H, Shudo K. Retinoids. Vitamin A for clinical applications. Farumashia 1990;26:35-40
79. Morriss-Kay GM. Retinoids: their physiological function and therapeutic potential. Adv Organ Biol 1997;3:79
80. Moon RC, Mehta RG. Anticarcinogenic effects of retinoids in animals. Adv Exp Med Biol 1986;206:399-411
81. Patel RN, Chu L, Chidambaram R, et al. Enantioselective microbial reduction of 2-oxo-2-(1′,2′,3′,4′-tetrahydro- 1′,1′,4′,4′-tetramethyl- 6′-naphthalenyl)acetic acid and its ethyl ester. Tetrahedron:Asymmetry 2002;13(4):349-55
82. Fukuroda T, Nishikibe M. Enhancement of pulmonary artery contraction induced by endothelin-β receptor antagonism. J Cardiovasc Pharmacol 1998;31:169-71
83. Sumner MJ, Cannon TR, Mundin JW, et al. Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br J Pharmacol 1992;107(3):858-60
84. Krulewicz B, Tschaen D, Devine P, et al. Asymmetric biosynthesis of key aromatic intermediates in the synthesis of an endothelin receptor antagonist. Biocatalysis Biotransformation 2001; 19(4):267-79
85. Holton R, Biediger R, Boatman D. Semisynthesis of taxol and taxotere. In: Taxol: Science and Application. Suffness M, editor, CRC Press, NY. 1995. p. 97-121
86. Patel RN. Tour de paclitaxel: biocatalysis for semisynthesis. Annu Rev Microbiol 1995;98:361-95
87. Patel RN, Banerjee A, Howell JM, et al. Microbial synthesis of (2R,3S)-(-)-N-benzoyl-3-phenyl isoserine ethyl ester, a taxol side-chain synthon. Tetrahedron: Asymmetry 1993;4(9):2069-84
88. Junien JL, Leonard BE. Drugs acting on sigma and phencyclidine receptors: a review of their nature, function, and possible therapeutic importance. Clin Neuropharmacol 1989;12(5);353-74
89. Ferris, CD, Hirsch DJ, Brooks BP, et al. σ Receptors: from molecule to man. J Neurochem 1991;57(3):729-37
90. Patel RN, Banerjee A, Liu M, et al. Microbial reduction of 1-(4-fluorophenyl)-4-[4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl] butan-1-one. Biotechnol Appl Biochem 1993;17(2):139-53
91. Coleman PJ, Brashear KM, Askew BC, Nonpeptide α vβ 3 antagonists. Part 11. Discovery and preclinical evaluation of potent α vβ 3 antagonists for the prevention and treatment of osteoporosis. J Med Chem 2004;47(20):4829-37
92. Pollard DJ, Telari K, Lane J et al. Asymmetric reduction of alpha, beta-unsaturated ketone to (R) allylic alcohol by Candida chilensis. Biotechnol Bioeng 2006;93:674-86
93. Brands KMJ, Payack JF, Rosen JD, et al. Efficient synthesis of NK1 receptor antagonist aprepitant using a crystallization - induced diastereoselective transformation. J Am Chem Soc 2003;125(8):2129-35
94. Pollard D, Truppo M, Pollard J, et al. Effective synthesis of (S)-3,5-bistrifluoro methylphenyl ethanol by asymmetric enzymatic reduction. Tetrahedron:Asymmetry 2006;17(4):554-9
95. Truppo MD, Pollard D, Devine P. Enzyme-catalyzed enantioselective diaryl ketone reductions. Org Lett 2007; 9(2):335-8
96. Pianko S, McHutchison JG. Treatment of hepatitis C with interferon and ribavirin. J Gastroenterol Hepatol 2000;15(6):581-6
97. Ferenci P, Brunner H, Nachbaur K, et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001;34(5):1006-11
98. Bonkovsky HL, Stefancyk D, McNeal K, et al. Comparative effects of different doses of ribavirin plus interferon-α2b for therapy of chronic hepatitis C: results of a controlled, randomized trial. Dig Dis Sci 2001;46(10):2051-9
99. Tamarez M, Morgan B, Wong GSK, et al. Pilot-scale lipase-catalyzed regioselective acylation of ribavirin in anhydrous media in the synthesis of a novel prodrug intermediate. Org Proc Res Dev 2003;7(6):951-3
100. Cossy J, Schmitt A, Cinquin C, et al. A very short, efficient and inexpensive synthesis of the prodrug form of SC-54701A a platelet aggregation inhibitor. Bioorg Med Chem Lett 1997;7(13):1699-700
101. Yamanaka T, Ohkubo M, Takahashi F, et al. An efficient synthesis of the orally-active GpIIb/IIIa antagonist FR184764. Tetrahedron Lett 2004;45(13):2843-5
102. Landis BH, Mullins PB, Mullins KB, et al. Kinetic resolution of β-amino esters by acylation using immobilized penicillin amidohydrolase. Org Proc Res Dev 2002;6(4):539-46
103. Njoroge FG, Taveras AG, Kelly J, et al. (+)-4-[2-[4-(8-Chloro-3, 10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]-pyridin-11 (R)-yl)-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent. J Med Chem 1998;41:4890-902
104. Morgan B, Zaks A, Dodds DR, et al. Enzymatic kinetic resolution of piperidine atropisomers: synthesis of a key intermediate of the farnesyl protein transferase inhibitor, SCH66336. J Org Chem 2000;65(18):5451-9
105. Ireland C, Leeson PA, Castaner J. Lobucavir. Antiviral Drugs Future 1997;22(4):359-70
106. Hanson RL, Shi Z, Brzozowski DB, et al. Regioselective enzymatic aminoacylation of lobucavir to give an intermediate for lobucavir prodrug. Bioorg Med Chem 2000;8(12):2681-7
107. Umezawa H, Kondo S, Iinuma H, et al. Structure of an antitumor antibiotic, spergaulin. J Antibiot 1981;34(12):1622-4
108. Umeda Y, Moriguchi M, Ikai K, et al. Synthesis and antitumor activity of spergualin analogues. III. Novel method for synthesis of optically active 15-deoxyspergualin and 15-deoxy-11-O-methylspergualin. J Antibiot 1987;40(9):1316-24
109. Patel RN, Banerjee A, Szarka LJ. Stereoselective acetylation of [1-(hydroxy)-4-(3-phenoxyphenyl)butyl] phosphonic acid diethyl ester. Tetrahedron:Asymmetry 1997; 8(7):1055-9
110. Maeda K, Umeda Y, Saino T. Synthesis and background chemistry of 15-deoxyspergualin. Ann NY Acad Sci 1993;685:123-35
111. Sit SY, Parker BA, Motoc I, et al. Synthesis, biological profile, and quantitative structure-activity relationship of a series of novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. J Med Chem 1990;33(11):2982-99
112. Patel RN, McNamee CM, Szarka LJ. Enantioselective enzymic acetylation of racemic [4-[4α,6β(E)]]-6-[4,4-bis (4-fluorophenyl)-3-(1-methyl-1H-tetrazol-5-yl)-1,3-butadienyl] tetrahydro-4-hydroxy-2H-pyran-2-one. Appl Microbiol Biotechnol 1992;38:56-60
113. Schenk D, Games D, Seubert P. Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Aβ immunization. J Mol Neurosci 2001;17(2):259-67
114. Audia JE, James E, Britton TC, et al. Preparation of N-(phenylacetyl) di- and tripeptide derivatives for inhibiting β-amyloid peptide release. WO9822494 (1998)
115. Patel RN, Banerjee A, Nanduri VB, et al. Enzymatic resolution of racemic secondary alcohols by lipase B from Candida antarctica. J Am Oil Chem Soc 2000;77(10):1015-9
116. Bisacchi G, Slusarchyk WA, Treuner U, et al. Preparation of amidino and guanidine azetidinone compounds as tryptase inhibitors. WO9967215 (1999)
117. Goswami A, Howell JM, Hua EY, et al. Chemical and enzymatic resolution of (R,S)-N-(tert-butoxycarbonyl)-3-hydroxymethylpiperidine. Org Proc Res Dev 2001;5(4):415-20
118. Gibson DT, Parales RE. Aromatic hydrocarbon dioxygenases in environmental biotechnology. Curr Opin Biotech 2000;11(3):236-43
119. Parales RE, Resnick SM. Applications of aromatic hydrocarbon dioxygenases. Biocatalysis in the Pharmaceutical and Biotechnology Industries. Patel RN, editor, CRC Press, FL. 2007. p. 299-331
120. Yeh WK, Gibson DT, Liu T-N. Toluene dioxygenase: a multicomponent enzyme system. Biochem Biophys Res Commun 1977:78(1):401-10
121. Lee K, Friemann R, Parales JV, et al. Purification, crystallization and preliminary X-ray diffraction studies of the three components of the toluene 2,3-dioxygenase enzyme system. Acta Crystallograph Sect F Struct Biol Cryst Commun F61 2005;7:669-72
122. Karlsson A, Parales JV, Parales RE, et al. Crystal structure of naphthalene dioxygenase: side-on binding of dioxygen to iron. Science 2003; 299(5609):1039-42
123. Hudlicky T, Gonzalez D, Gibson DT. Enzymatic dihydroxylation of aromatics in enantioselective synthesis: expanding asymmetric methodology. Aldrichimica Acta 1999;32(2):35-62
124. Boyd DR, Sharma ND, Allen CCR. Aromatic dioxygenases: molecular biocatalysis and applications. Curr Opin Biotechnol 2001; 12(6):564-73
125. Boyd DR, Bugg TDH. Arene cis-dihydrodiol formation: from biology to application. Org Biomol Chem 2006;4(2):181-92
126. Boyd DR, Sharma ND, Coen GP, et al. Enzyme-catalysed synthesis and absolute configuration assignments of cis-dihydrodiol metabolites from 1,4-disubstituted benzenes. Chem A Eur J 2007;13(20):5804-11
127. Chartrain M, Jackey B, Taylor C, et al. Bioconversion of indene to cis-(1S,2R)-indandiol and trans-(1R,2R)-indandiol by Rhodococcus sp. J Ferment Technol 1998;86:550-8
128. Buckland BC, Robinson DK, Chartrain M. Biocatalysis for pharmaceuticals-status and prospects for a key technology. Metab Eng 2000;2:42-8
129. Chartrain M, Salmon PM, Robinson DK, et al. Metabolic engineering and directed evolution for the production of pharmaceuticals. Curr Opin Biotechnol 2000;11:209-14
130. Zhang N, Stewart BG, Moore IC, et al. Directed evolution of toluene dioxygense from Pseudomonas putida for improved selectivity toward cis-(1S,2R)-indanediol during indane. Metab Eng 2000;2(4):339-48
131. Amanullah A, Hewitt CJ, Nienow AW, et al. Measurement of strain-dependent toxicity in the indene bioconversion using multiparameter flow cytometry. Biotechnol Bioeng 2003;81(4):405-20
132. Edwards G, Weston AH. Potassium channel openers and vascular smooth muscle relaxation. Pharmacol Ther 1990;48(2):237-58
133. Robertson DW, Steinberg MI. Potassium channel openers: new biological probes. Annu Rep Med Chem 1989;24:91-100
134. Hamilton TC, Weston AH. Cromakalim, nicorandil and pinacidil: novel drugs which open potassium channels in smooth muscle. Gen Pharmacol 1989;20(1):1-9
135. Ashwood VA, Buckingham RE, Cassidy F, et al. Synthesis and antihypertensive activity of 4-(cyclic amido)-2H-1-benzopyrans. J Med Chem 1986;29(11):2194-201
136. Patel RN, Banerjee A, Davis B, et al. Stereoselective epoxidation of 2,2-dimethyl-2H-1-benzopyran-6-carbonitrile. Bioorg Med Chem 1994;2(6):535-42
137. Parker WB, White EC, Shaddix SC, et al. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases α, β, and γ by the 5′-triphosphates of carbovir, 3′-azido-3′-deoxythymidine, 2′,3′-dideoxyguanosine, and 3′-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs. J Biol Chem 1991;266(3):1754-62
138. Muenzer DF, Meinhold P, Peters MW, et al. Stereoselective hydroxylation of an achiral cyclopentanecarboxylic acid derivative using engineered P450s BM-3. Chem Commun (Cambridge, United Kingdom) 2005;20:2597-9
139. de Raadt A, Griengl H, Petsch M, et al. Microbial hydroxylation of 2-cycloalkylbenzoxazoles. Part III. Determination of product enantiomeric excess and cleavage of benzoxazoles. Tetrahedron:Asymmetry 1996;7(2):491-6
140. Urlacher VB, Lutz-Wahl S, Schmid RD. Microbial P450 enzymes in biotechnology. Appl Microbiol Biotechnol 2004;64(3):317-25
141. Li Q-S, Schwaneberg U, Fischer M, et al. Rational evolution of a medium chain-specific cytochrome P-450 BM-3 variant. Biochim Biophys Acta 2001;1545(1-2):114-21
142. Arnold FH, Otey CR. Libraries of optimized cytochrome P450 enzymes and the optimized P450 enzymes exhibiting higher activities and new substrate specificities. WO2005017106 (2005)
143. Gerth K, Pradella S, Perlova O, et al. Myxobacteria: proficient producers of novel natural products with various biological activities-past and future biotechnological aspects with the focus on the genus Sorangium. J Biotechnol 2003; 106(2-3)233-53
144. Benigni D, Stankavage R, Chiang S-J, et al. Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B. WO2004026254 (2004)
145. Goodin S, Kane MP, Robin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004;22(1):2015-25
146. Nicolaou KC, Roschangar F, Vourloumis D. Chemical biology of epothilones. Angew Chem Int Ed 1998;37(15):2014-45
147. Altmann K-H. The merger of natural product synthesis and medicinal chemistry: on the chemistry and chemical biology of epothilones. Org Biomol Chem 2004;2(15):2137-52
148. Boddy CN, Hotta K, Tse ML, et al. Precursor-directed biosynthesis of epothilone in Escherichia coli. J Am Chem Soc 2004;126(24):7436-7
149. Lin N, Brakora K, Seiden M. BMS-247550 (Bristol-Myers Squibb/GBF). Curr Opin Investig Drugs 2003;4(6):746-56
150. Basch J, Chiang S-H. Cloning and expression of acytochrome P450 hydroxylase gene from Amycolatopsis orientalis: hydroxylation of epothilone B for the production of epothilone F. J Ind Microbiol Biotechnol 2007;34(2):171-6
151. Kolman A. BMS-310705 Bristol-Myers Squibb/GBF. Curr Opin Investig Drugs 2004;5(12):1292-7
152. Hoegenauer G. Mechanism of action of antibacterial agents. Tiamulin and pleuromutilin. Antibiotics (New York) 1979;5(1):344-60
153. Berner H, Vyplel H, Schulz C, et al. Chemistry of pleuromutilins. V. Photoisomerization of AB-trans-anellated mutilan-11-one. Tetrahedron 1983;39(10):1745-8
154. Hanson RL, Matson JA, Brzozowski DB, et al. Hydroxylation of mutilin by Streptomyces griseus and Cunninghamella echinulata. Org Proc Res Dev 2002;6(4):482-7
155. Springer DM, Sorenson ME, Huang S, et al. Synthesis and activity of a C-8 keto pleuromutilin derivative. Bioorg Med Chem Lett 2003;13(10):1751-3
156. Janssen DB. Dehalogenases in biodegradation and biocatalysis. In: Biocatalysis in the Pharmaceutical and Biotechnology Industries. Patel RN, editor, CRC Press, FL. 2007. p. 441-62
157. Kasai N, Suzuki T, Furukawa Y. Optically active chlorohydrins as chiral C3 and C4 building units: microbial resolution and synthetic applications. Chirality 1998;1097:682-92
158. Kasai N, Suzuki T. Industrialization of the microbial resolution of chiral C3 and C4 synthetic units: from a small beginning to a major operation, a personal account. Adv Synthesis Catalysis 2003;345(4):437-55
159. Suzuki T, Kasai N. A novel method for the generation of (R)- and (S)-3-chloro-1,2-propanediol by stereospecific dehalogenating bacteria and their use in the preparation of (R)- and (S)-glycidol. Bioorg Med Chem Lett 1991;1(7):343-6
160. Suzuki T, Idogaki H, Kasai N. A novel generation of optically active ethyl 4-chloro-3-hydroxybutyrate as a C4 chiral building unit using microbial dechlorination. Tetrahedron:Asymmetry 1996;7(11):3109-12
161. Tang L, Pazmino DET, Fraaije MW, et al. Improved catalytic properties of halohydrin dehalogenase by modification of the halide-binding site. Biochemistry 2005;44(17):6609-18
162. Tang L, van Hylckama Vlieg JET, et al. Improved stability of halohydrin dehalogenase from Agrobacterium radiobacter AD1 by replacement of cysteine residues. Enzyme Microb Technol 2002;30(2):251-8
163. Nakamura T, Nagasawa T, Yu F, et al. A new catalytic function of halohydrin hydrogen-halide-lyase, synthesis of β-hydroxynitriles from epoxides and cyanide. Biochem Biophys Res Commun 1991;180(1):124-30
164. Lutje Spelberg JHL, Tang L, van Gelder M, et al. Exploration of the biocatalytic potential of a halohydrin dehalogenase using chromogenic substrates. Tetrahedron:Asymmetry 2002;13(10):1083-9
165. Lutje Spelberg JH, van Hylckama Vlieg JET, Tang L, et al. Highly enantioselective and regioselective biocatalytic azidolysis of aromatic epoxides. Org Lett 2001;3(1):41-3
166. Lutje Spelberg JH, Tang L, Kellogg RM, et al. Enzymatic dynamic kinetic resolution of epihalohydrins. Tetrahedron: Asymmetry2004;15(7):1095-2
167. Hasnaoui G, Lutje Spelberg JH, de Vries E, et al. Nitrite-mediated hydrolysis of epoxides catalyzed by halohydrin dehalogenase from Agrobacterium radiobacter AD1: a new tool for the kinetic resolution of epoxides. Tetrahedron: Asymmetry 2005;16(9):1685-92
168. Elenkov MM, Hauer B, Janssen DB. Enantioselective ring opening of epoxides with cyanide catalyzed by halohydrin dehalogenases: a new approach to nonracemic β-hydroxy nitriles. Adv Synthesis Catalysis 2006; 348(4+5):579-85
169. Fessner W-D. Enzyme-catalyzed aldol additions. Mod Aldol React 2004; 1:201-72
170. Griengl H, Schwab H, Fechter M. The synthesis of chiral cyanohydrins by oxynitrilases. Trends Biotechnol 2000;18(6):252-6
171. Pohl M, Lingen B, Muller M. Thiamin-diphosphate-dependent enzymes: new aspects of asymmetric C-C bond formation. Chem A Eur J 2002;8(23):5288-95
172. Fessner W-D, Helaine V. Biocatalytic synthesis of hydroxylated natural products using aldolases and related enzymes. Curr Opin Biotechnol 2001;12(6):574-86
173. Sprenger GA, Pohl M. Synthetic potential of thiamin diphosphate-dependent enzymes. J Mol Catalysis B Enzymatic 1999;6(3):145-59
174. Ward OP, Singh A. Recent development in enzymatic acyloin condensations. In: Biocatalysis in the Pharmaceutical and Biotechnology Industries. Patel RN, editor. 2007. p. 605-21
175. Ohta H, Sugai T. Enzyme-mediated decarboxylase reactions in organic synthesis. In: Stereoselective Biocatalysis. Patel RN, editor, Marcel Dekker, NY. 2000. p. 487-526
176. Yagasaki M, Ozaki A. Industrial biotransformations for the production of D-amino acids. J Mol Catalysis B Enzymatic 1998;4(1-2):1-11
177. Prosen E, Ward OP, Collins S, et al. Enantiospecific production of (S)-2-hydroxypropiophenone mediated by benzoylformate decarboxylase from Acinetobacter calcoaceticus. Biocatalysis 1993;8(1):21-9
178. Demir AS, Dunnwald T, Iding H, et al. Asymmetric benzoin reaction catalyzed by benzoylformate decarboxylase. Tetrahedron:Asymmetry 1999;10(24):4769-74
179. Pohl M, Liese A. Industrial processes using lyases for C-C, C-N, and C-C bond formation. Biocatalysis in the Pharmaceutical and Biotechnology Industries. Patel RN, editor, CRC Press, FL. 2007. p. 661-76
180. Guo Z, Goswami A, Mirfakhrae KD, et al. Asymmetric acyloin condensation catalyzed by phenylpyruvate decarboxylase. Tetrahedron:Asymmetry 1999; 10(24):4667-75
181. Lee S-G, Hong S-P, Sung M-H. Development of an enzymatic system for the production of dopamine from catechol, pyruvate and ammonia. Enzyme Microb Technol1999;25:298-302
182. Abelyan VA, Abelyan LA. Production of L-lactic acid and L-malic acid by intact and immobilized cells of Lactobacillus casei. Appl Biochem Microbiol 1998;34:578-80
183. Wilcocks R, Ward OP, Collins S, et al. Acyloin formation by benzoylformate decarboxylase from Pseudomonas putida. Appl Environ Microbiol 1992; 5895:1699-704
184. Lingen B, Pohl M, Demir AS, et al. Enantioselective syntheses of hydtoxy ketones via benzoylformate decarboxylase- and benzaldehyde lyase-catalyzed C-C bond formation. Oxidative Stress Dis 2004;11:113-29
185. Lingen B, Groetzinger J, Kolter D, et al. Improving the carboligase activity of benzoylformate decarboxylase from Pseudomonas putida by a combination of directed evolution and site-directed mutagenesis. Protein Eng 2002; 15(7):585-93
186. Dean SM, Greenberg WA, Wong C-H. Recent advances in aldolase-catalyzed asymmetric synthesis. Adv Synthesis Catalysis 2007;349(8+9):1308-20
187. Look GC, Gary C, Fotsch CH, et al. Enzyme-catalyzed organic synthesis: practical routes to aza sugars and their analogs for use as glycoprocessing inhibitors. Acc Chem Res 1993;26:282-90
188. Kajimoto T, Chen L, Liu KKC, Wong C-H. Palladium-mediated stereocontrolled reductive amination of azido sugars prepared from enzymic aldol condensation: a general approach to the synthesis of deoxy az94a sugars. J Am Chem Soc 1991; 113(17):6678-80
189. Ziegler T, Straub OA, Effenberger F. Enzyme-catalyzed reactions. 3. Enzyme-catalyzed synthesis of deoxymannojirimycin, 1-deoxynojirimycin and 1,4-dideoxy-1,4-imino-D-arabinitol. Angew Chem 1988;100(5):737-38
190. Kajimoto T, Liu KKC, Pederson RL, et al. Enzyme-catalyzed aldol condensation for asymmetric synthesis of azasugars: synthesis, evaluation, and modeling of glycosidase inhibitors. J Am Chem Soc 1991; 113(16):6187-96
191. Romero A, Wong C-H. Chemo-enzymatic total synthesis of 3-epiaustraline, australine, and 7-epialexine. J Org Chem 2000;65(24):8264-8
192. Henderson DP, Shelton MC, Cotterill IC, et al. Stereospecific preparation of the N-terminal amino acid moiety of Nikkomycins KX and KZ via a multiple enzyme synthesis. J Org Chem 1997;62(23):7910-11
193. Sugai T, Lin CH, Shin GJ, et al. CMP-KDO synthetase: overproduction and application to the synthesis of CMP-KDO and analogs. Bioorg Med Chem 1995;3(3):313-20
194. Blayer S, Woodley JM, Lilly MD, et al. Characterization of the chemoenzymic synthesis of N-acetyl-D-neuraminic acid (Neu5Ac). Biotechnol Prog 1996;12(6):758-63
195. Mahmoudian M, Noble D, Drake CS, et al. An efficient process for production of N-acetylneuraminic acid using N-acetylneuraminic acid aldolase. Enzyme Microbial Technol 1997; 20(5):393-400
196. Kragl U, Gygax D, Ghisalba O, et al. Enzymatic, two-step synthesis of N-acetylneuraminic acid in a enzyme-membrane reactor. Angew Chem 1991;103(7):854-5
197. Gijsen HJM, Wong C-H. Sequential three- and four-substrate aldol reactions catalyzed by aldolases. J Am Chem Soc 1995;117(29):7585-91
198. Greenberg WA, Varvak A, Hanson SR et al. Development of an efficient, scalable, aldolase-catalyzed process for enantioselective synthesis of statin intermediates. Proc Natl Acad Sci USA 2004;101(16):5788-93
199. Veronesi B, Carter JD, Devlin RB, et al. Neuropeptides and capsaicin stimulate the release of inflammatory cytokines in a human bronchial epithelial cell line. Neuropeptides (Edinburgh) 1999;33(6):447-56
200. Yuan L, Burcher E, Nail BS. Characterization of tachykinin receptors mediating bronchomotor and vasodepressor responses to neuropeptide γ and substance P in the anesthetized rabbit. Pulm Pharmacol Ther 1998; 11(1):31-9
201. Ting PC, Lee JF, Anthes JC, et al. Synthesis and NK1/NK2 receptor activity of substituted 4(Z)-(methoxyimino) pentyl-1-piperazines. Bioorg Med Chem Lett 2000;10(20):2333-5
202. Reichard GA, Ball ZT, Aslanian R, et al. The design and synthesis of novel NK1/NK2 dual antagonists. Bioorg Med Chem Lett 2000; 10(20):2329-32
203. Homann MJ, Vail R, Morgan B, et al. Enzymatic hydrolysis of a prochiral 3-substituted glutarate ester, an intermediate in the synthesis of an NK1/NK2 dual antagonist. Adv Synthesis Catalysis 2001;343(6-7):744-9
204. Suen W-C, Zhang N, Xiao L, et al. Improved activity and thermostability of Candida antarctica lipase B by DNA family shuffling. Protein Eng Design Sel 2004;17(2):133-40
205. Zhang N, Suen W-C, Windsor W, et al. Improving tolerance of Candida Antarctica lipase B towards irreversible thermal inactivation through directed evolution. Protein Eng 2003;16(8):599-605
206. DeSantis G, Wong K, Farwell B, et al. Creation of a productive, highly enantioselective nitrilase through gene site saturation mutagenesis (GSSM). J Am Chem Soc 2003;125(38):11476-7
207. DeSantis C, Zhu Z, Greenberg WA, et al. An enzyme library approach to biocatalysis: development of nitrilases for enantioselective production of carboxylic acid derivatives. J Am Chem Soc 2002;124(31):9024-5
208. Desantis G, Short JM, Burk M, et al. Identification, cloning, sequences and design of nitrilases for synthesis of enantioselective amino acids and hydroxy acids. WO2003097810 (2003)
209. Robertson DE, Chaplin JA, DeSantis G, et al. Exploring nitrilase sequence space for enantioselective catalysis. Appl Environ Microbiol 2004;70(4):2429-36
210. Bloom JD, Datta MD, Johnson BD, et al. Disodium (R,R)5-[2-(3-chlorophenyl)-2 hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2 dicarboxylate. A potent adrenergic agonist virtually specific for 3 receptors. J Med Chem 1989;35:3081-4
211. Fisher LG, Sher PM, Skwish S, et al. BMS-187257, a potent, selective, and novel heterocyclic-3 adrenergic receptor agonist. Bioorg Med Chem Lett 1994;6:2253-8
212. Patel RN, Banerjee A, Chu L, et al. Microbial synthesis of chiral intermediates for 3-receptor agonists. J Am Oil Chem Soc 1998;75:1473-82
213. Holton R, Biediger R, Joatman P. Semisynthesis of taxol and taxotere. In: Taxol: Science and Application. Suffness M, editor, CRC Press, NY. 1995. p. 97-123
214. Baloglu E, Kingston DG. A new semisynthesis of paclitaxel from baccatin III. J Nat Prod 1999;62(7):1068-71
215. Patel RN, Banerjee A, Ko RY, et al. Enzymic preparation of (3R-cis)-3-(acetyloxy)-4-phenyl-2-azetidinone: a taxol side-chain synthon. Biotechnol Appl Biochem 1994;20(1):23-33
216. Rose WC, Long BH, Fairchild CR, et al. Preclinical pharmacology of BMS-275183, an orally active taxane. Clin Cancer Res 2001;7(7):2016-21
217. Patel RN, Howell JM, Chidambaram R, et al. Enzymatic preparation of (3R)-cis-3-acetyloxy-4-(1,1-dimethylethyl)-2-azetidinone: a side-chain synthon for an orally active taxane. Tetrahedron: Asymmetry 2003;14(23):3673-7
218. Archelas A, Furstoss R. Synthetic applications of epoxide hydrolases. Curr Opin Chem Biol 2001;5(2):112-9
219. Steinreiber A, Faber K. Microbial epoxide hydrolases for preparative biotransformations. Curr Opin Biotechnol 2001;12(6):552-8
220. Catt JD, Johnson G, Keavy DJ, et al. Preparation of benzofuran and dihydrobenzofuran melatonergic agents. US5856529 (1999)
221. Goswami A, Totleben MJ, Singh AK, et al. Stereospecific enzymatic hydrolysis of raemic epoxide: a process for making chiral epoxide. Tetrahedron:Asymmetry 1999;10(16):3167-75
222. Voelkert M, Koul S, Mueller GH, et al. Phenylhydrazide as an enzyme-labile protecting group in peptide synthesis. J Org Chem 2002;67(20):6902-10
223. Costello CA, Kreuzmann AJ, Zmijewski MJ. Selective deprotection of phthalyl-protected amines. Tetrahedron Lett 1996;37(42):7469-72
224. Bommarius AS, Drauz K, Gunther K, et al. L-methionine related L-amino acids by acylase cleavage of their corresponding N-acetyl-DL-derivatives. Tetrahedron: Asymmetry 1997;8(19):3197-200
225. Ogawa J, Shimizu S. Stereoselective synthesis using hydantoinases and carbamoylases. In: Stereoselective Biocatalysis. Patel RN, editor, Marcel Dekker, NY. 2000. p. 1-21
226. Sajiki H, Hattori K, Hirora K: The formation of a novel Pd/ C-ethylenediamine complex catalyst: hemoselective hydrogenation without deprotection of the O-benzyl and N-cbz groups. J Org Chem 1998;63(22):7990-2
227. Royer GP, Chow W, Hatton KS. Palladium/polyethylenimine catalysts. J Mol Catalysis 1985;31(1):1-13
228. Patel RN, Nanduri V, Brzozowski D, et al. Enantioselective enzymatic cleavage of N-benzyloxycarbonyl groups. Adv Synthesis Catalysis 2003; 345(6+7):830-4
229. Nanduri VB, Goldberg S, Johnston R, et al. Cloning and expression of a novel enantioselective N-carbobenzyloxy-cleaving enzyme. Enzyme Microbial Technol 2004;34(3+4):304-12
230. Rudroff F, Rydz J, Ogink FH, et al. Comparing the stereoselective biooxidation of cyclobutanones by recombinant strains expressing bacterial Baeyer-Villiger monooxygenases. Adv Synthesis Catalysis 2007;349(8+9):1436-44
231. Iwaki H, Wang S, Grosse S, et al. Pseudomonad cyclopentadecanone monooxygenase displaying an uncommon spectrum of Baeyer-Villiger oxidations of cyclic ketones. Appl Environ Microbiol 2006;72(4):2707-20
232. Mihovilovic MD, Snajdrova R, Groetzl B. Microbial Baeyer-Villiger oxidation of 4,4-disubstituted cyclohexan- and cyclohexenones by recombinant whole-cells expressing monooxygenases of bacterial origin. J Mol Catalysis B Enzymatic 2006;39(1-4):135-40
233. Alphand V, Furstoss R. Microbiological transformations 22. Microbiologically mediated Baeyer-Villiger reactions: a unique route to several bicyclic gamma-lactones in high enantiomeric purity. J Org Chem 1989;57:1306-9
234. Kamberbeek NM, Janssen DB, van Berkel WJH, et al. Baeyer-Villiger monooxygenases, an emerging family of flavin-dependent biocatalysts. Adv Synthesis Catalysis 2003; 345:667-78
235. Mihovilovic MD, Mueller B, Stanetty. Monooxygenase-mediated Baeyer-Villiger oxidation. Eur J Org Chem 2002;22:3711-30
236. Stewart JD. Cyclohexanone monooxygenase: a useful reagent for asymmetric Baeyer Villiger reactions. Curr Org Chem 1998;2:195-216
237. Hiker I, Wohlgemuth R, Alphand V, et al. Microbial transformations 59: first kilogram scale asymmetric microbial Baeyer-Villiger oxidation with optimized productivity using a resin-based in situ SFPR strategy. Biotechnol Bioeng 2005;92(6):702-10
238. Rudroff F, Alphand V, Furstoss R, et al. Optimizing fermentation conditions of recombinant Escherichia coli expressing cyclopentanone monooxygenase. Org Proc Res Dev 2006;10(3):599-604
239. Cernuchova P, Mihovilovic MD. Microbial Baeyer-Villiger oxidation of terpenones by recombinant whole-cell biocatalysts-formation of enantiocomplementary regioisomeric lactones. Org Biomol Chem 2007;5(11):1715-9
240. Hilker I, Gutierrez MC, Alphand V, et al. Microbiological transformations 57. Facile and efficient resin-based in situ SFPR preparative-scale synthesis of an enantiopure "unexpected" lactone regioisomer via a Baeyer-Villiger oxidation process. Org Lett 2004;6(12):1955-8
241. Pazmino DET, Snajdrova R, Rial DV, et al. Altering the substrate specificity and enantioselectivity of phenylacetone monooxygenase by structure-inspired enzyme redesign. Adv Synthesis Catalysis 2007;349(8+9):1361-8
242. Kim M-J, Ahn Y, Park J. Dynamic kinetic resolution and asymmetric transformations by enzyme-metal combinations. In: Biocatalysis in the Pharmaceutical and Biotechnology Industries. Patel RN, editor, CRC Press, FL. 2007. p. 249-72
243. Martin-Mature B, Baeckvall J-E. Dynamic kinetic resolution catalyzed by enzymes and metals. Curr Opin Chem Biol 2007;11(2):226-32
244. Simeo Y, Kroutil W, Faber K. Biocatalytic deracemization: dynamic resolution, stereoinversion, enantioconvergent processes, and cyclic deracemization. In: Biocatalysis in the Pharmaceutical and Biotechnology Industries. Patel RN, editor, CRC Press, FL. 2007. p. 27-51
245. Turner NJ. Enzyme catalyzed deracemization and dynamic kinetic resolution reactions. Curr Opin Chem Biol 2004;8(2):114-9
246. Pamies O, Baeckvall J-E. Dynamic kinetic resolution of β-azido alcohols. An efficient route to chiral aziridines and β-amino alcohols. J Org Chem 2001; 66(11):4022-5
247. Archer I, Carr R, Fotheringham I, et al. Synthesis of enantiopure amino acids and amines. Concerted use of a biocatalyst and a chemocatalyst. Chimica e l'Industria (Milan, Italy) 2005;87(6):100-4
248. Carr R, Alexeeva M, Dawson MJ, et al. Directed evolution of oxidase for the preparative deracemization of cyclic secondary amines. Chem Bio Chem 2005;6:637-9
249. Roff GJ, Lloyd RC, Turner NJ. A versatile chemo-enzymatic route to enantiomerically pure β-branched α-amino acids. J Am Chem Soc 2004;126(13):4098-9
250. Zhu Y, Pow K-L, Chuah G-K, et al. Dynamic kinetic resolution of secondary alcohols combining enzyme-catalyzed transesterification and zeolite-catalyzed racemization. Chem A Eur J 2007;13(2):541-7
251. Boren L, Martin-Matute B, Xu Y, et al. (S)-selective kinetic resolution and chemoenzymatic dynamic kinetic resolution of secondary alcohols. Chem A Eur J 2005;12(1):225-32
252. Kim M-J, Kim HM, Kim D, et al. Dynamic kinetic resolution of secondary alcohols by enzyme-metal combinations in ionic liquid. Green Chem 2004; 6(9):471-4
253. Lee HK, Kim D, Park J. (S)-Selective dynamic kinetic resolution of secondary alcohols by the combination of subtilisin and an aminocyclopentadienyl ruthenium complex as the catalysts. J Am Chem Soc 2003;125:11494-5
254. Verzijl GKM, De Vries JG, Broxterman QB. Process for the preparation of enantiomerically enriched esters and alcohols. WO2001090396 (2001)
255. Allan GR, Carnell AJ. Microbial deracemization of 1-aryl and 1-heteroaryl secondary alcohols. J Org Chem 2001;66(19):6495-7
256. Azerad R, Buisson D. Dynamic resolution and stereoinversion of secondary alcohols by chemo-enzymatic processes. Curr Opin Biotechnol 200;11(6):565-71
257. Kroutil W, Faber K. Deracemization of compounds possessing a sec-alcohol or -amino group through a cyclic oxidation-reduction sequence: a kinetic treatment. Tetrahedron:Asymmetry 1998;9(16):2901-13
258. Carnell AJ. Stereoinversions using microbial redox-reactions. Adv Biochem Eng Biotechnol 1999; 63(Biotransformations):57-72
259. Comasseto V, Omori AT, Andrade LH, et al. Bioreduction of fluoroacetophenones by the fungi Aspergillus terreus and Rhizopus oryzae. Tetrahedron:Asymmetry 2003;14:711-5
260. Broxterman QB, Verzijl GKM. Process for the synthesis of (R)-1-(3,5-bis(trifluoromethyl)phenyl) ethan-1-ol and esters thereof by dynamic kinetic resolution. WO2003043575 (2003)
261. Strubing D, Krumlinde P, Piera J, et al. Dynamic kinetic resolution of primary alcohols with an unfunctionalized stereogenic center in the β-position. Adv Synthesis Catalysis 2007;349(10):1577-81
262. Demir AS, Hamamci H, Sesenoglu O, et al. Fungal deracemization of benzoin. Tetrahedron Lett 2002;43:6447-9
263. Kato D, Mitsuda S, Ohta H. Microbial deracemization of α-substituted carboxylic acids. Org Lett 2002;4:371-3
264. Kato D, Mitsuda S, Ohta H. Microbial deracemization of α-substituted carboxylic acids: substrate specificity and mechanistic investigation. J Org Chem 2003;68:7234-42
265. Pamies O, Baeckvall JE. An efficient route to chiral α- and β-hydroxyalkanephosphonates. J Org Chem 2003;68(12):4815-18
266. Paedragosa-Moreau S, Morisseau C, Baratti J, et al. Microbiological transformations. 37. An enantioconvergent synthesis of the β-blocker (R)-nifenalol using a combined chemoenzymic approach. Tetrahedron 1997;53(28):9707-14
267. Orru, RVA, Archelas A, Furstoss R, et al. Epoxide hydrolases and their synthetic applications. Adv Biochem Eng Biotechnol (Biotransformations) 1999;63:145-67
268. Archer, IVJ, Leak DJ, Widdowson DA. Chemoenzymic resolution and deracemization of (±)-1-methyl-1,2-epoxycyclohexane: the synthesis of (1-S,2-S)-I-methylcyclohexane-1,2 diol. Tetrahedron Lett 1996;37(48):8819-22
269. Ueberbacher BJ, Osprian I, Mayer SF, et al. A chemoenzymatic, enantioconvergent, asymmetric total synthesis of (R)-fridamycin E. Eur J Org Chem 2005;7:1266-70
270. Monfort N, Archelas A, Furstoss R. Enzymatic transformations. Part 55. Highly productive epoxide hydrolase catalyzed resolution of an azole antifungal key synthon. Tetrahedron 2004;60(3):601-5
271. Karboune S, Archelas A, Baratti J. Properties of epoxide hydrolase from Aspergillus niger for the hydrolytic kinetic resolution of epoxides in pure organic media. Enzyme Microbial Technol 2006;39(2):318-24
272. Goswami A, Mirfakhrae KD, Patel RN. Deracemization of racemic 1,2-diol by biocatalytic stereoinversion. Tetrahedron: Asymmetry 1999;10(21):4239-44
273. Fransson AL, Boren L, Pamies O, et al. Kinetic resolution and chemoenzymatic dynamic kinetic resolution of functionalized γ-hydroxy amides. J Org Chem 2005;70(7):2582-7
274. Martin-Mature B, Baeckvall JE. Ruthenium- and enzyme-catalyzed dynamic kinetic asymmetric transformation of 1,4-diols: synthesis of γ-hydroxy ketones. J Org Chem 1994;69(26):9191-5
275. MacDonald M, D'Cunha GB. A modern view of phenylalanine ammonia lyase. Biochem Cell Biol 2007;85(3):273-82
276. Effenberger F, Foerster S, Kobler C. State of the art and applications in stereoselective synthesis of chiral cyanohydrins. In: Biocatalysis in the Pharmaceutical and Biotechnology Industries. CRC Press, FL. 2007. p. 698
277. Gotor V. Lipases and (R)-oxynitrilases: useful tools in organic synthesis. J Biotechnol 2002;96(1):35-42
278. Fechter MH, Griengl H. Hydroxynitrile yases: biological sources and application as biocatalysts. Food Technol Biotechnol 2004;42(4):287-94
279. Effenberger F, Forster S, Wajant H. Hydroxynitrile lyases in stereoselective catalysis. Curr Opin Biotechnol 2000;11(6):532-9
280. Poechlauer P. Syntheses of homochiral cyanohydrins in an industrial environment. Hydroxy nitrile lyases offer new options. Chim Oggi 1998;16(5):15-19
281. Johnston DV, Zabelinskaja AA, Griengl H. Oxynitrilases for asymmetric C-C bond formation. Curr Opin Chem Biol 2000;4:103-9
282. Tsuchida T, Nishimoto Y, Kotani T, liizumi K. Jpn Kokai Tokkyo Koho Manufacture of L-3,4-dihydroxyphenylalanine with Erwinia.1993, 7 pp. JP 05123177 A 19930521 Heisei. CAN 119:93708, AN 1993:493708
283. Yamada H. In: Screening for Microbial Biocatalysis. Kieslich K, van der Beck CP, deBont JAM, editors, Studien in Organic Chemistry, Elsevier:Amsterdam 1998;53:13
284. Purkarthofer T, Pabst T, Van den Broek C, et al. Large-scale synthesis of (R)-2-amino-1-(2-furyl)ethanol via a chemoenzymatic approach. Org Process Res Dev 2006;10(3):618-21
285. Purkarthofer T, Thomas S, Wolfgang S, et al. Potential and capabilities of hydroxynitrile lyases as biocatalysts in the chemical industry. Appl Microbiol Biotechnol 2007;76(2):309-20
286. Groger H. Enzymatic routes to enantiomerically pure aromatic α-hydroxy carboxylic acids: a further example for the diversity of biocatalysis. Adv Synthesis Catalysis 2001;343(6+7):547-58
287. Glieder A, Weis R, Skranc W, et al. Comprehensive step-by-step engineering of an (R)-hydroxynitrile lyase for large-scale asymmetric synthesis. Angew Chem Int Ed 2003;42(39):4815-8
288. Pochlauer P, Schmidt M, Wirth I, et al. Enzymatic process for the preparation of (S)-cyanohydrins. Eur Pat Appl 1999, 14 pp. EP 927766 A1 19990707 CAN 131:72766 AN 1999:440051
289. Avi M, Fechter MH, Gruber K, et al. Hydroxynitrile lyase catalyzed synthesis of heterocyclic (R)- and (S)-cyanohydrins. Tetrahedron 2004; 60(46):10411-8
290. Roberge C, Fleitz F, Pllard D, Devine P. Synthesis of optically active cyanohydrins from aromatic ketones: evidence of an increased substrate range and inverted stereoselectivity for the hydroxynitrile lyase from Linum usitarissimum. Tetrahdron Lett 2007;48:1473-7 reduction of